A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Overview

This is an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus vaccine.

Full Title of Study: “A Single-center, Dose-escalation, Open-label Pilot Study to Evaluate the Safety and Tolerability of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2016

Interventions

  • Biological: Staphylococcus aureus vaccine (60µg/per protein)
    • two doses of 60µg/0.6ml per dose
  • Biological: Staphylococcus aureus vaccine (30µg/per protein)
    • two doses of 30µg/0.6ml per dose
  • Biological: Staphylococcus aureus vaccine (15µg/per protein)
    • two doses of 15µg/0.6ml per dose

Arms, Groups and Cohorts

  • Experimental: High dosage vaccine
    • High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
  • Experimental: Middle dosage vaccine
    • Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
  • Experimental: Low dosage vaccine
    • Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)

Clinical Trial Outcome Measures

Primary Measures

  • Occurrence of solicited adverse reactions after vaccination.
    • Time Frame: within 0-14 days after the vaccination
    • Occurrence of solicited site adverse reactions within 0-14 days after vaccination with the Recombinant Staphylococcus aureus vaccine (Escherichia coli).

Secondary Measures

  • Occurrence of unsolicited adverse reactions after vaccination.
    • Time Frame: within 0-35 days after the vaccination
    • Occurrence of unsolicited adverse reactions within 0-35 days after vaccination with the Recombinant Staphylococcus aureus vaccine (Escherichia coli).
  • Occurrence of serious adverse events after the vaccination.
    • Time Frame: within 6 months after the vaccination
    • Occurrence of serious adverse events within 6 months after the vaccination with the Recombinant Staphylococcus aureus vaccine (Escherichia coli).
  • Changes of the laboratory examinations after vaccination.
    • Time Frame: day 3 after the vaccination
    • Changes of the laboratory examinations after vaccination with the Recombinant Staphylococcus aureus vaccine (Escherichia coli) on day 3.
  • Changes of the laboratory examinations after vaccination.
    • Time Frame: day 7 after the vaccination
    • Changes of the laboratory examinations after vaccination with the Recombinant Staphylococcus aureus vaccine (Escherichia coli) on day 7.
  • Changes of the laboratory examinations after vaccination.
    • Time Frame: day 10 after the vaccination
    • Changes of the laboratory examinations after vaccination with the Recombinant Staphylococcus aureus vaccine (Escherichia coli) on day 10.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy volunteers aged 18 to 65 years (aged over 18 and under 66 years).
  • Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.
  • Able to understand the content of informed consent and willing to sign the informed consent.
  • Able to complete the diary card independently.
  • For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.
  • Axillary temperature ≤37.0°C.

Exclusion Criteria

First Immunization exclusion standard:

  • Prior receipt of Staphylococcus aureus vaccine
  • Any confirmed Staphylococcus aureus infection disease in the past 12 month.
  • History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.
  • Prior blood donation or Blood loss over 400ml in the last 3 months;
  • Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.
  • History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain.
  • Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease.
  • Taking immunoglobulins and/or any blood products within the last 12 months.
  • Asplenia, functional asplenia or asplenia caused by any situation or splenectomy.
  • Any acute disease or acute attack of chronic disease in last 7 days.
  • History of thyroidectomy or thyroid disease requiring treatment in the last 12 months.
  • Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and non-concurrent corticosteroids treatment)
  • Participation in another research study involving receipt of an investigational product in the last 30 days.
  • Woman who is breast-feeding.
  • Prior administration of attenuated vaccine in last 28 days.
  • Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.
  • Current anti-tuberculosis prophylaxis or therapy
  • Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.

Following Immunization exclusion standard:

  • Any grade 3 or more serious adverse reaction happen since the last vaccination.
  • Other condition violates the inclusion criteria or meets the exclusion criteria is noticed after the first immunization.
  • Acute or chronic infections at the vaccination day (axillary temperature>37.0°C).
  • According to the investigator, the participant should not continue participating in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jiangsu Province Centers for Disease Control and Prevention
  • Collaborator
    • Chengdu Olymvax Biopharmaceuticals Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Fengcai Zhu, Professor – Jiangsu Province Centers for Disease Control and Prevention

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.